Haloperidol and reduced haloperidol concentrations in plasma and red blood cells from chronic schizophrenic patients

Journal of Clinical Psychopharmacology

Volumn 9, Issue 3, 1989, Pages 186-190

  Ko, Grant N ^a   Korpi, Esa R ^b   Kirch, Darrell G ^c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b ALKO Limited   (Finland)

^c NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HALOPERIDOL;

ADULT; CLINICAL ARTICLE; DRUG BLOOD LEVEL; ERYTHROCYTE; HUMAN; ORAL DRUG ADMINISTRATION; SCHIZOPHRENIA; SERUM;

ADOLESCENT; ADULT; CHRONIC DISEASE; CLINICAL TRIALS; DOUBLE-BLIND METHOD; ERYTHROCYTES; FEMALE; HALOPERIDOL; HUMAN; MALE; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 0024312571     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/00004714-198906000-00005     Document Type: Article

References (31)

1. Forsman A, Ohman R. Applied pharmacokinetics of haloperidol in man. Curr Ther Res 1977;21:396–411.
2. Forsman A, Ohman R. Studies on serum protein binding of haloperidol. Curr Ther Res 1977;21:245–55.
3. Forsman A, Ohman R. Pharmacokinetic studies on haloperidol in man. Curr Ther Res 1976;20:319–36.
4. Forsman A, Larsson M. Metabolism of haloperidol. Curr Ther Res 1978;24:567–8.
5. Korpi ER, Wyatt RJ. Reduced haloperidol: effects on striatal dopamine metabolism and conversion to haloperidol in the rat. Psychopharmacology 1984;83:34–7.
6. Kirch DG, Palmer MR, Egan M, Freedman R. Electrophysiological interactions between haloperidol and reduced haloperidol, and dopamine, norepinephrine and phencyclidine in rat brain. Neuropharmacology 1985;24:375–9.
7. Korpi ER, Costakos DT, Wyatt RJ. Interconversions of haloperidol and reduced haloperidol in guinea pig and rat liver microsomes. Biochem Pharmacol 1985;34:2923–7.
8. Korpi ER, Kleinman JE, Costakos DT, Linnoila M, Wyatt RJ. Reduced haloperidol in the post-mortem brains of haloperidol-treated patients. Psychiatry Res 1984;11:259–69.
9. Korpi ER, Phelps BH, Granger H, Chang W-H, Linnoila M, Meek JL, Wyatt RJ. Simultaneous determination of haloperidol and its reduced metabolite in serum and plasma by isocratic liquid chromatography with electrochemical detection. Clin Chem 1983;29:624–8.
10. Volavka J, Cooper TB. Review of haloperidol blood level and climcal response: looking through the window. J Clin Psychopharmacol 1987;7:25–30.
11. Garver DL, Dekirmenjian H, Davis JH, Casper K, E ricksen S. Neuroleptic drug levels and therapeutic response: preliminary observations with red blood cell bound butaperazine. Am J Psychiatry 1977;134:304–7.
12. Garver DL, Hirschowitz J, Glickstein GA, et al. Haloperidol plasma and red blood cell levels and chemical antipsychotic response. J Clin Psychopharmacol 1984;4:133–7.
13. Garver DL, Davis JM, Dekirmenjian H, Jones FD, Casper K, Haraszti J. Pharmacokinetics of red cell phenothiazine and clincial effects. Arch Gen Psychiatry 1976;33:862–6.
14. Garver DL, Davis JM, Dekirmenjian H, Ericksen S, Gosenfeld L, Haraszti J. Dystonic reactions following neuroleptics: time course and proposed mechanisms. Psychopharmacology 1976;47:199–201.
15. Neborsky R, Janowsky DS, Perel J, Munson E, Depry D. Haloperidol plasma/red cell ratios and clinical efficacy. Psychopharmacol Bull 1984;18:17–20.
16. Neborsky R, Janowsky DS, Perel JM, Munson E, Depry D. Plasma/RBC haloperidol ratios and improvement in acute psychotic symptoms. J Clin Psychiatry 1984;45:10–3.
17. Shvartsburd A, Dekirmenjian H, Smith RC. Blood levels of haloperidol in schizophrenic patients. J Clin Psychopharmacol 1983;3:7–12.
18. Smith RC, Vroulis G, Shvartsburd A, Allen R, Lewis N, Schoolar JC, Chojnacki M, Johnson R. RBC and plasma blood levels of haloperidol and clinical response in schizophrenia. Am J Psychiatry 1982;139:1054–6.
19. Diagnostic and Statistical Manual of Mental Disorders, 3rd ed. Washington, DC: American Psychiatric Association, 1980.
20. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep 1979;10:799–812.
21. Levene H. Robust tests for equality of variance. In: Olkin I, ed. Contributions to probability and statistics. Palo Alto, CA: Stanford University Press 1960;278–92.
22. Ereshefsky L, Davis CM, Harrington CA, Jann MW, Browning JL, Saklad SR, Burch NR. Haloperidol and reduced haloperidol plasma levels in selected schizophrenic patients. J Clin Psychopharmacol 1984;4:138–42.
23. Browning JL, Harrington CA, Davis CM. Quantitation of haloperidol and reduced haloperidol by radioimmunoassay. J Immunoassay 1985;6:45–66.
24. Browning JL, Harrington CA, Burch NR. Quantification of haloperidol and reduced haloperidol metabolites in plasma of psychiatric patients. Fed Proc 1982;41:1635.
25. Altamura AC, Mauri MC, Cavallaro R, Gorni A. Haloperidol metabolism and antipsychotic effect in schizophrenia. Lancet 1:1987;814–5.
26. Shostak M, Perel JM, Stiller RL, Wyman W, Curran S. Plasma haloperidol and clinical response: a role for reduced haloperidol in antipsychotic activity? J Clin Psychopharmacol 1987;7:394–400.
27. Kirch DG, Bigelow LB, Korpi ER, Wagner RL, Zalcman S, Wyatt RJ. Serum haloperidol concentration and clinical response in schizophrenia. Schizophr Bull 1988;14:283–289.
28. Midha KK, Hawes EM, Hubbard JW, Korchinski ED, McKay G. Interconversion between haloperidol and reduced haloperidol in humans. J Clin Psychopharmacol 1987;7:362–3.
29. Seeman P, Lee T, Chan-Wong M. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 1976;261:717–9.
30. Creese I, Burt DR, Snyder SH. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 1976;192:481–3.
31. Rothpearl AB, Mohs RC, Davis KL. Statistical power in biological psychiatry. Psychiatry Res 1981;5:257–66.